Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avanos Medical (AVNS – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Privia Health Group (PRVA – Research Report).
Avanos Medical (AVNS)
Stifel Nicolaus analyst Rick Wise maintained a Hold rating on Avanos Medical yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $29.01.
According to TipRanks.com, Wise is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Avanos Medical with a $25.50 average price target, representing a -20.2% downside. In a report released today, JMP Securities also reiterated a Hold rating on the stock.
See the top stocks recommended by analysts >>
Crispr Therapeutics AG (CRSP)
In a report released yesterday, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Crispr Therapeutics AG, with a price target of $69.00. The company’s shares closed last Tuesday at $46.63, close to its 52-week low of $38.94.
According to TipRanks.com, Burnett has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $82.50 average price target, implying a 66.8% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock.
Privia Health Group (PRVA)
Stifel Nicolaus analyst Michael Craig Jones maintained a Buy rating on Privia Health Group yesterday and set a price target of $32.00. The company’s shares closed last Tuesday at $27.77.
Jones has an average return of
According to TipRanks.com, Jones is ranked #1546 out of 8343 analysts.
Currently, the analyst consensus on Privia Health Group is a Strong Buy with an average price target of $36.00, implying a 30.1% upside from current levels. In a report issued on February 20, Jefferies also maintained a Buy rating on the stock with a $43.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVNS:
